II. Epidemiology
- Most common cause of Thyrotoxicosis in the United States (up to 60-80% of cases)
- Prevalence: 20 to 50 in 100,000
- Gender: More common in women
III. Pathophysiology
- Autoimmune disorder
- Thyroid stimulating antibodies bind TSH receptors, resulting in Thyroid Hormone synthesis and release
- Associated with Thyroid Gland hyperplasia and Goiter
IV. Risk Factors
- Female gender (RR 4 compared with males)
- Autoimmune Disorder
- Family History of Graves Disease (or other autoimmune disorder)
- Tobacco Abuse
- Iodine exposure
V. Findings
- See Hyperthyroidism
- Older patients may present less specifically (e.g. Fatigue, weight loss, Atrial Fibrillation)
VI. Signs: Specific to Grave's Disease
- See Hyperthyroidism
- Diffuse, smooth Goiter
- Palpated thrill or audible bruit over Thyroid
- Infiltrative ophthalmopathy or orbitopathy (Thyroid Eye Disease)
- Ophthalmoplegia
- Proptosis (Exophthalmos) in 25-50% of cases
- Periorbital swelling
- Dermopathy
- Pretibial Myxedema (Thyroid dermopathy, 1.5% of cases)
- Swelling over the tibia
- Peau d' orange skin changes
- Thyroid Acropachy
- Hand soft tissue swelling and Digital Clubbing
- Skin Pigment Changes
- Patchy Hyperpigmentation or vitilgo
- Pretibial Myxedema (Thyroid dermopathy, 1.5% of cases)
VII. Differential Diagnosis
- See Hyperthyroidism
VIII. Labs
- See Hyperthyroidism
-
Thyroid Stimulating Immunoglobulin (TSH Receptor Antibody)
- Test Sensitivity: 97%
- Test Specificity: >=98%
- Linked with ophthalmopathy
- May be used to monitor effects of treatment
- Usually not needed for diagnosis
- However, may be used in lieu of Thyroid uptake scan in Grave's Disease diagnosis
-
Antithyroid Peroxidase Antibody negative
- Contrast with positive in Hashimoto's Thyroiditis
IX. Imaging
-
Thyroid uptake and scan (first-line study)
- Diffusely high Radioactive Iodine uptake
- Thyroid Ultrasound with doppler (if performed)
- Thyroid hypervascularity with increased flow
X. Management
- See Hyperthyroidism Management
- Referral to ophthalmology for ocular involvement
- Antithyroid Medications (Thionamides)
- Indications
- Grave's Disease without Goiter
- Thionamides are first-line treatment
- Result in euthyroid state within 18 months in up to 50%
- Grave's Disease without Goiter
- Medications
- Methimazole 15-30 mg per day (up to 120 mg)
- Propylthiouracil (PTU) 100-200 mg orally every 8 hours
- Indicated in pregnancy first trimester
- Monitoring
- See Antithyroid Medications
- Thyroid function
- First: T4 Free, Total T3 every 4-6 weeks until euthyroid
- Next: TSH, T4 Free every 3-6 months
- Adverse Effects
- Agranulocytosis (CBC)
- Hepatotoxicity (LFT)
- Efficacy: Predictors of remission with Thionamides
- TSH Receptor Antibody negative
- Non-smoker
- Female Gender
- Indications
-
Radioactive Iodine (RAI)
- Indications
- Failed remission with Thionamides after 12-24 months
- High dose Thionamides required or adverse effects
- Toxic Multinodular Goiter
- Contraindications
- Efficacy
- Effective in Graves Disease in >90% of patients
- Monitoring
- Thyroid Function Tests every 4-6 weeks
- Anticipate Hypothyroidism in up to 86% of Graves Disease patients treated with RAI
- Precautions
- RAI exacerbates Thyroid Eye Disease, esp. in smokers (pretreat with Corticosteroids)
- Indications
-
Thyroidectomy
- See Thyroidectomy for indications